842 related articles for article (PubMed ID: 28125989)
1. An inverse association between serum soluble receptor of advanced glycation end products and hyperandrogenism and potential implication in polycystic ovary syndrome patients.
Liao Y; Huang R; Sun Y; Yue J; Zheng J; Wang L; Tao T; Ma J; Li S; Liu W
Reprod Biol Endocrinol; 2017 Jan; 15(1):9. PubMed ID: 28125989
[TBL] [Abstract][Full Text] [Related]
2. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
Li X; Lin JF
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
[TBL] [Abstract][Full Text] [Related]
3. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome.
Diamanti-Kandarakis E; Katsikis I; Piperi C; Alexandraki K; Panidis D
Clin Endocrinol (Oxf); 2007 Jan; 66(1):103-9. PubMed ID: 17201808
[TBL] [Abstract][Full Text] [Related]
4. Are plasma levels of visfatin and retinol-binding protein 4 (RBP4) associated with body mass, metabolic and hormonal disturbances in women with polycystic ovary syndrome?
Olszanecka-Glinianowicz M; Madej P; Zdun D; Bożentowicz-Wikarek M; Sikora J; Chudek J; Skałba P
Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):55-61. PubMed ID: 22397743
[TBL] [Abstract][Full Text] [Related]
5. Soluble receptor for advanced glycation end products as a potential biomarker to predict weight loss and improvement of insulin sensitivity by a very low calorie diet of obese human subjects.
Hagen I; Schulte DM; Müller N; Martinsen J; Türk K; Hedderich J; Schreiber S; Laudes M
Cytokine; 2015 Jun; 73(2):265-9. PubMed ID: 25802195
[TBL] [Abstract][Full Text] [Related]
6. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome.
Diamanti-Kandarakis E; Piperi C; Kalofoutis A; Creatsas G
Clin Endocrinol (Oxf); 2005 Jan; 62(1):37-43. PubMed ID: 15638868
[TBL] [Abstract][Full Text] [Related]
7. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS).
Diamanti-Kandarakis E; Katsikis I; Piperi C; Kandaraki E; Piouka A; Papavassiliou AG; Panidis D
Clin Endocrinol (Oxf); 2008 Oct; 69(4):634-41. PubMed ID: 18363886
[TBL] [Abstract][Full Text] [Related]
8. Serum leptin levels correlate with clinical and biochemical indices of insulin resistance in women with polycystic ovary syndrome.
Pehlivanov B; Mitkov M
Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):153-9. PubMed ID: 19340711
[TBL] [Abstract][Full Text] [Related]
9. [Exploration of the classification of polycystic ovarian syndrome].
Lin JF; Li X; Zhu MW
Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
[TBL] [Abstract][Full Text] [Related]
10. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case-control study.
Singh S; Akhtar N; Ahmad J
Diabetes Metab Syndr; 2012; 6(4):207-11. PubMed ID: 23199540
[TBL] [Abstract][Full Text] [Related]
11. Circulating osteopontin and its association with liver fat content in non-obese women with polycystic ovary syndrome: a case control study.
Wang Y; Zhou W; Wu C; Zhang Y; Lin T; Sun Y; Liu W; Tao T
Reprod Biol Endocrinol; 2018 Mar; 16(1):31. PubMed ID: 29587769
[TBL] [Abstract][Full Text] [Related]
12. Heterogenous origins of hyperandrogenism in the polycystic ovary syndrome in relation to body mass index and insulin resistance.
Patlolla S; Vaikkakara S; Sachan A; Venkatanarasu A; Bachimanchi B; Bitla A; Settipalli S; Pathiputturu S; Sugali RN; Chiri S
Gynecol Endocrinol; 2018 Mar; 34(3):238-242. PubMed ID: 29068242
[TBL] [Abstract][Full Text] [Related]
13. Serum soluble receptor for advanced glycation end products correlates inversely with measures of adiposity in young adults.
Davis KE; Prasad C; Vijayagopal P; Juma S; Imrhan V
Nutr Res; 2014 Jun; 34(6):478-85. PubMed ID: 25026914
[TBL] [Abstract][Full Text] [Related]
14. The association of the lipidomic profile with features of polycystic ovary syndrome.
Moran LJ; Mundra PA; Teede HJ; Meikle PJ
J Mol Endocrinol; 2017 Jul; 59(1):93-104. PubMed ID: 28500248
[TBL] [Abstract][Full Text] [Related]
15. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome.
Yildiz BO; Yarali H; Oguz H; Bayraktar M
J Clin Endocrinol Metab; 2003 May; 88(5):2031-6. PubMed ID: 12727950
[TBL] [Abstract][Full Text] [Related]
16. Serum HLA-G levels in women with polycystic ovary syndrome.
Oztekin O; Fenkci SM; Fenkci V; Enli Y; Cabus U
Gynecol Endocrinol; 2015 Mar; 31(3):243-6. PubMed ID: 25403326
[TBL] [Abstract][Full Text] [Related]
17. Body composition, glucose metabolism markers and serum androgens - association in women with polycystic ovary syndrome.
Kozakowski J; Zgliczyński W
Endokrynol Pol; 2013; 64(2):94-100. PubMed ID: 23653271
[TBL] [Abstract][Full Text] [Related]
18. The correlation of plasma omentin-1 with insulin resistance in non-obese polycystic ovary syndrome.
Yang HY; Ma Y; Lu XH; Liang XH; Suo YJ; Huang ZX; Lu DC; Qin YF; Luo ZJ
Ann Endocrinol (Paris); 2015 Oct; 76(5):620-7. PubMed ID: 26514948
[TBL] [Abstract][Full Text] [Related]
19. [Insulin resistance and serum concentrations of ovarian and adrenal androgen in obese women without additional disease and with policystic ovary syndrome].
Olszanecka-Glinianowicz M; Banaś M; Zahorska-Markiewicz B; Kuglin D; Mokrzycka J; Mentel A
Endokrynol Pol; 2005; 56(6):921-6. PubMed ID: 16821212
[TBL] [Abstract][Full Text] [Related]
20. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
